Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  GenSight Biologics S.A.    SIGHT   FR0013183985

GENSIGHT BIOLOGICS S.A.

(SIGHT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

GenSight Biologics S A : Submits EU Marketing Authorisation Application for LUMEVOQ Gene Therapy to Treat Vision Loss due to Leber Hereditary Optic Neuropathy

share with twitter share with LinkedIn share with facebook
09/16/2020 | 09:54am EDT

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it has submitted the Marketing Authorisation Application (MAA) for its lead product LUMEVOQ to the European Medicines Agency (EMA), seeking approval for the treatment of patients with vision loss due to Leber Hereditary Optic Neuropathy (LHON) caused by mutation in the ND4 mitochondrial gene.

'This first regulatory submission for GenSight is a major milestone in our progression from a pure research organization to one with commercial capabilities. It validates a technology platform that has the potential to address the high unmet medical needs of patients suffering from a range of rare diseases. I would like to thank all GenSight employees and partners whose motivation, focus and effort made this submission possible,' said Bernard Gilly, Co-founder and Chief Executive Officer of GenSight Biologics.

LHON is a rare, mitochondrial genetic disease, mainly affecting young males. The ND4 mutation results in the worst visual outcomes, with most patients becoming legally blind. There continues to be a high unmet medical need for the 800-1200 new LHON patients in Europe and the U.S. each year, particularly those who are struck blind in their prime working years.

Lenadogene nolparvovec (tradename: LUMEVOQ) is a recombinant adeno-associated viral vector, serotype 2 (rAAV2/2), containing a cDNA encoding the human wild-type mitochondrial NADH dehydrogenase 4 protein (ND4), which has been specifically developed for the treatment of LHON associated with mutation in the ND4 gene. It received orphan drug designation status for the treatment of LHON from the EMA in 2011 and from the U.S. Food and Drug Administration (FDA) in 2013.

GenSight submitted the MAA based on the benefit-risk balance established by results from a Phase-I/IIa study (CLIN-01), two pivotal Phase-III efficacy studies (CLIN-03A: RESCUE, and CLIN-03B: REVERSE) and the long-term follow up study of RESCUE and REVERSE (CLIN 06 - readout at Year 3 post injection). To demonstrate the efficacy of LUMEVOQ in the context of a contralateral effect, the Company used a statistics-based indirect comparison methodology to assess the visual outcomes in LUMEVOQ-treated patients (from LUMEVOQ efficacy studies) against those in untreated patients from Natural History studies and GenSight's REALITY Natural History Registry.

GenSight expects to submit the Biologics License Application (BLA) for LUMEVOQ to the FDA in H2 2021. First-in-human data from GenSight's second clinical stage program, GS030, are expected to be available in H2 2021.

About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, LUMEVOQ (GS010; lenadogene nolparvovec), is in Phase III trials in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to the eye by intravitreal injection to offer patients a sustainable functional visual recovery.

Contact:

Thomas Gidoin

Tel: +33 (0)1 76 21 72 20

Email: tgidoin@gensight-biologics.com

(C) 2020 Electronic News Publishing, source ENP Newswire


share with twitter share with LinkedIn share with facebook
All news about GENSIGHT BIOLOGICS S.A.
10/23GENSIGHT BIOLOGICS S A : successfully raises EUR25 million in an oversubscribed ..
AQ
10/22GENSIGHT BIOLOGICS S A : Securities Note
PU
10/22GENSIGHT BIOLOGICS S A : Amendment to the 2019 Universal Registration Document
PU
10/22GENSIGHT BIOLOGICS S A : launches a capital increase of approximately EUR25 mill..
AQ
10/22GENSIGHT BIOLOGICS S A : successfully raises Ä25 million in an oversubscribed pr..
PU
10/22GENSIGHT BIOLOGICS S A : Successfully Raises Ä25 Million in an Oversubscribed Pr..
BU
10/21GENSIGHT BIOLOGICS S A : launches a capital increase of approximately Ä25 millio..
PU
10/16GENSIGHT BIOLOGICS S A : Reports Cash Position as of September 30, 2020 and Prov..
AQ
10/15GENSIGHT BIOLOGICS S A : Appoints Elsy Boglioli to its Board of Directors
AQ
10/15GENSIGHT BIOLOGICS S A : Reports Cash Position as of September 30, 2020 and Prov..
PU
More news
Financials
Sales 2020 12,5 M 14,6 M 14,6 M
Net income 2020 -16,7 M -19,5 M -19,5 M
Net cash 2020 16,7 M 19,5 M 19,5 M
P/E ratio 2020 -6,13x
Yield 2020 -
Capitalization 144 M 168 M 169 M
EV / Sales 2020 10,2x
EV / Sales 2021 9,55x
Nbr of Employees 25
Free-Float 97,8%
Chart GENSIGHT BIOLOGICS S.A.
Duration : Period :
GenSight Biologics S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENSIGHT BIOLOGICS S.A.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 10,23 €
Last Close Price 3,64 €
Spread / Highest target 285%
Spread / Average Target 181%
Spread / Lowest Target 84,1%
EPS Revisions
Managers
NameTitle
Bernard Jacques Alex Gilly Chief Executive Officer & Director
Michael S. Wyzga Chairman
Thomas Gidoin Chief Financial Officer
Magali Taiel Chief Medical Officer
Josť-Alain Sahel Director
Sector and Competitors
1st jan.Capitalization (M$)
GENSIGHT BIOLOGICS S.A.46.48%168
GILEAD SCIENCES, INC.-9.93%73 380
REGENERON PHARMACEUTICALS48.02%58 486
VERTEX PHARMACEUTICALS-5.45%53 919
WUXI APPTEC CO., LTD.71.35%40 739
BEIGENE, LTD.80.68%27 143